Awards Header 5


The World ADC Awards Judges are handpicked for their longstanding familiarity and deep knowledge of the ADC field.

Jagath Junutula, VP, Cellerant Therapeutics

Judge 1

Dr. Jagath Reddy Junutula joined Cellerant in April 2014 as a Vice President, Antibody Discovery & Development. Prior to joining Cellerant, Jagath was at Genentech for 13 years focusing on oncology drug discovery and development, including discovery and validation of targets for treatment of cancer; design, development and pre-clinical validation of antibody drug conjugates (ADCs); engineering next-generation ADCs; and development of bi-specific antibody/protein based cancer immunotherapeutic platforms for treatment of different types of cancers. He developed a novel THIOMAB technology platform to generate site-specific antibody-drug conjugates (ADCs) to improve the therapeutic utility of antibodies. This technology has widely been accepted as a new standard for the development of therapeutic ADCs. He obtained his PhD in 1997 from the Indian Institute of Science, Bangalore, India, and did post-doctoral research in Germany as an Alexander von Humboldt fellow and at Stanford University. Jagath has authored 60 peer-reviewed publications/patents and has presented his work at numerous international conferences. Jagath serves as an editorial board member of leading antibody therapeutics journal, mAbs.

David Meininger, Executive Director, Merck

Emerging Leaders Program - portrait for Sync profile. 2012

Dr. David Meininger joined Merck in 2011 as Head of Protein Sciences. He served as a member of the Biologics Review & Licensing Committee, as champion of the Adimab collaboration, as co-champion of the Ambrx antibody-drug conjugate collaboration and played a strategic role on other Merck partnerships. In 2013, Dr. Meininger joined the new Merck Research Labs Business Development & Licensing organization. His BD&L responsibilities include evaluation and transaction of in- and out-licensing deals involving biologic assets from pre-clinical through phase II, support of the Merck Research Ventures Fund team and other BD activities. Prior to joining Merck, Dr. Meininger held positions with Amgen, Boehringer Ingelheim, Genentech, and Tularik. Dr. Meininger holds a Ph.D. in Chemistry from the University of California, San Diego, a M.B.A. in Technology Management from the University of Washington and a B.S. in Chemistry from the University of Florida.

Ho Cho, VP, Celgene

Judge 2

Dr. Ho Sung Cho is VP, Biotherapeutics at Celgene. Dr. Cho is a Protein Medicinal Chemist with over 24 years of experience in recombinant protein expression, purification, modification, and analysis. Prior to joining industry, Dr. Cho worked on the structural genomics project at the Lawrence Berkeley National Labs. He received his Ph. D. in Chemistry from the University of California at Berkeley.